Abstract
Safety and efficacy of topically applied gel H-100 composed of Nicardipine, superoxide dismutase and emu oil for treatment of acute phase Peyronie’s disease (PD) was evaluated. Twenty-two patients (PD <12 months duration) were studied in a prospective, randomized, double-blind, placebo-controlled study. Eleven patients received H-100 and 11 patients received placebo for 3 months. All 22 patients then received H-100 for the final 3 months. Flaccid-stretched penile length, degree of penile curvature, pain level and side effects were assessed monthly. H-100 showed significant improvement in all PD parameters at 6 months: mean stretched penile length increase (22.6%, P=0.0002), mean curvature reduction (40.8%, P=0.0014), and mean pain level reduction (85.7%, P=0.004). Placebo group showed no significant improvement except for mean stretched penile length increase (6.8%, P=0.009). Crossover patients from placebo to H-100 showed significant improvement in all parameters: mean stretched penile length increase (17.5%, P=0.000007), mean curvature reduction (37.1%, P=0.006), and mean pain level reduction (40%, P=0.17). Treatment was well tolerated. A self-limited rash was the only side effect in three patients. Statistically significant improvements in flaccid-stretched penile length, curvature and pain suggest that H-100 is a safe and possibly effective non-invasive, topically applied treatment for acute phase Peyronie’s Disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
02 June 2020
A Correction to this paper has been published: https://doi.org/10.1038/s41443-020-0303-z
References
Ralph D, Gonzales-Cadavid N, Mirone V, Perevic S, Sohn M, Usta M et al. The management of Peyronie’s disease: evidence-based 2010 guidelines. J Sex Med 2010; 7: 2359–2374.
Hellstrom W . Medical management of Peyronie’s disease. J Androl 2009; 30: 397–405.
Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J et al. Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie's disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013; 190: 199–207.
Zemtsov A, Gaddis M, Montalvo-Lugo V . Moisturizing and Cosmetic Properties of Emu Oil: A Double Blind Study. Australas J Dermatol 1996; 37: 159–161.
Qiu XW, Wang JH, Fang XW, Gong ZY, Li ZQ, Yi ZH . Anti-inflammatory activity and healing-promoting effects of topical application of emu oil on wound in scalded rats. [Article in Chinese]. Di Yi Jun Yi Da Xue Xue Bao 2005; 25: 407–410.
Kouoh F, Gressier B, Dine T, Luyckx M, Brunet C, Ballester L et al. Antioxidant effects and anti-elastase activity of the calcium antagonist nicardipine on activated human and rabbit neutrophils—a potential antiatherosclerotic property of calcium antagonists? Cardiovasc Drugs Ther 2002; 16: 515–520.
Kinnula V, Crapo JD . Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med 2003; 167: 16001619.
Levine L, Rybak J, Corder C, Farrel MR . Peyronie’s disease plaque calcification-prevalence, time to identification, and development of a new grading classification. J Sex Med 2013; 10: 3121–3128.
Nelsen C, Diblasio C, Kendirci M, Hellstrom W, Gurhing P, Mulhall J . The chronology of depression and distress in men with Peyronie’s disease. J Sex Med 2008; 5: 1985–1990.
Martin DJ, Badwan K, Parker M, Mulhall JP . Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002; 168: 2483–2485.
Smith P, Craig-Schmidt M, Brown A . Fatty acid analysis of emu oil. INFORM 1995; 6: 450.
Yoganathan S, Nicolosi R, Wilson T, Handelman G, Scollin P, Tao R et al. Antagonism of croton oil inflammation by topical emu oil in CD-1 mice. Lipids 2003; 38: 603–607.
Fitch WP, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M . Topical verapamil HCL, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie’s disease-a placebo-controlled pilot study. J Sex Med 2007; 4: 477–484.
Levine L, Goldman K, Greenfield J . Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol 2002; 168: 168621–168626.
Soh J, Kawauchi A, Kanemitsu N, Naya Y, Ochial A, Naltoh Y et al. Nicardipine vs saline injection as treatment for Peyronie’s disease: a prospective, randomized, single-blind study. J Sex Med 2010; 7: 3743–3749.
Gurdal H, Sara Y, Tulunay FC . Effects of calcium channel blockers on formalin-induced nociception and inflammation in rats. Pharmacology 1992; 44: 290–296.
Halliwell B . Biochemical mechanisms accounting for the toxic action of oxygen on living organisms: the key role of superoxide dismutase. Cell Biol Int Rep 1978; 2: 113–128.
Riedl C, Sternig P, Galle G, Langmann F, Vcelar B, Vorauer K et al. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie’s disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol 2005; 48: 656–661.
Levine L, Burnett A . Standard operating procedures for Peyronie's disease. J Sex Med 2013; 10: 230–244.
Acknowledgements
We thank Harold Hoium, MBA, for contributions to study design, IRB compliance, ClinicalTrials.gov registration, coordination of drug development, database development, statistical analysis and statistics write-up. Statistical analysis was completed using standard features in Microsoft Excel.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on International Journal of Impotence Research website
Supplementary information
Rights and permissions
About this article
Cite this article
Twidwell, J., Levine, L. Topical treatment for acute phase Peyronie’s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study. Int J Impot Res 28, 41–45 (2016). https://doi.org/10.1038/ijir.2015.22
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijir.2015.22
This article is cited by
-
Transdermal application of H100 gel to the penile shaft in patients with Peyronie’s disease infiltrates the tunica albuginea
International Journal of Impotence Research (2024)
-
A systematic review of non-surgical management in Peyronieʼs disease
International Journal of Impotence Research (2023)
-
Conservative Therapy for Peyronie’s Disease: a Contemporary Review of the Literature
Current Urology Reports (2021)
-
Nonsurgical management of Peyronie’s disease
Nature Reviews Urology (2019)
-
Management of the Acute Phase of Peyronie’s Disease: a Contemporary Review
Current Sexual Health Reports (2019)